Analysts Set Definitive Healthcare Corp. (NASDAQ:DH) PT at $2.77

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have received an average rating of “Hold” from the eight brokerages that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $2.7667.

Several research analysts have weighed in on the stock. Zacks Research upgraded shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Robert W. Baird set a $1.10 price objective on shares of Definitive Healthcare in a report on Friday, May 8th. Barclays lowered their target price on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a report on Monday, March 30th. Stephens lowered their target price on shares of Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Friday, February 27th. Finally, Canaccord Genuity Group lowered their target price on shares of Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating for the company in a report on Friday, February 27th.

Institutional Trading of Definitive Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Definitive Healthcare in the second quarter valued at about $32,000. State of Alaska Department of Revenue raised its holdings in shares of Definitive Healthcare by 109.3% in the fourth quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after purchasing an additional 5,970 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Definitive Healthcare in the 4th quarter valued at $35,000. SG Americas Securities LLC bought a new position in Definitive Healthcare in the 4th quarter valued at $46,000. Finally, ExodusPoint Capital Management LP bought a new position in Definitive Healthcare in the 4th quarter valued at $47,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Stock Performance

DH opened at $0.84 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.81. The company’s fifty day moving average price is $0.95 and its two-hundred day moving average price is $1.63. Definitive Healthcare has a 1-year low of $0.80 and a 1-year high of $4.70. The company has a market cap of $88.58 million, a price-to-earnings ratio of -0.52, a PEG ratio of 11.29 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. The firm had revenue of $55.93 million for the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, analysts expect that Definitive Healthcare will post 0.05 EPS for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.